CymaBay Therapeutics (CBAY) – Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of CymaBay Therapeutics (NASDAQ: CBAY) recently:

  • 3/1/2019 – CymaBay Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company’s lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. “
  • 3/1/2019 – CymaBay Therapeutics was given a new $30.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 2/28/2019 – CymaBay Therapeutics was given a new $20.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 2/27/2019 – CymaBay Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 2/22/2019 – CymaBay Therapeutics is now covered by analysts at Leerink Swann. They set an “outperform” rating and a $22.00 price target on the stock.
  • 2/21/2019 – CymaBay Therapeutics had its “outperform” rating reaffirmed by analysts at Svb Leerink Llc.
  • 2/20/2019 – CymaBay Therapeutics was given a new $30.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 2/19/2019 – CymaBay Therapeutics had its “buy” rating reaffirmed by analysts at Roth Capital.
  • 2/15/2019 – CymaBay Therapeutics was given a new $18.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 2/7/2019 – CymaBay Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 2/6/2019 – CymaBay Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company’s lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. “
  • 2/5/2019 – CymaBay Therapeutics is now covered by analysts at B. Riley. They set a “hold” rating and a $9.00 price target on the stock.
  • 2/1/2019 – CymaBay Therapeutics had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock. They wrote, “. Reiterate our Overweight rating; increasing 12-mo. PT to $20. CymaBay is a liver disease company with lead asset, seladelpar, in Ph3 for primary biliary cholangitis (PBC). Our checks suggest seladelpar’s strong profile in PBC has the potential to grow the market significantly from where it is today. We think the opportunity in PBC alone (~$350M in 2026 unadjusted sales vs. cap of $500M) should justify upside. We see further potential for seladelpar with a 2Q19 Ph2b NASH proof of concept readout, which could be a much larger opportunity (~ $4B+) for Seladelpar if successful. In our 75-page slide deck, we took a close look at PPAR-delta biology & role in NASH. Our Take: PPAR-delta has the potential to be a major target in the NASH space.””
  • 1/31/2019 – CymaBay Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 1/24/2019 – CymaBay Therapeutics was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 1/21/2019 – CymaBay Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company’s lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California. “

Shares of NASDAQ:CBAY traded down $0.15 during trading on Friday, hitting $12.85. 938,842 shares of the company traded hands, compared to its average volume of 733,036. The firm has a market capitalization of $773.11 million, a PE ratio of -10.20 and a beta of 1.82. CymaBay Therapeutics Inc has a one year low of $6.31 and a one year high of $15.00.

In related news, Director Kurt Von Emster sold 142,381 shares of the stock in a transaction that occurred on Tuesday, December 18th. The stock was sold at an average price of $7.89, for a total value of $1,123,386.09. Following the completion of the transaction, the director now directly owns 90,000 shares of the company’s stock, valued at approximately $710,100. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Carl Goldfischer sold 11,675 shares of the stock in a transaction that occurred on Thursday, February 7th. The stock was sold at an average price of $9.02, for a total value of $105,308.50. Following the completion of the transaction, the director now directly owns 2,335 shares of the company’s stock, valued at $21,061.70. The disclosure for this sale can be found here. 4.50% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the stock. Fosun International Ltd bought a new stake in CymaBay Therapeutics in the 3rd quarter valued at $5,147,000. Nexthera Capital LP grew its holdings in CymaBay Therapeutics by 9.7% during the 3rd quarter. Nexthera Capital LP now owns 908,664 shares of the biopharmaceutical company’s stock valued at $10,068,000 after buying an additional 80,009 shares in the last quarter. Carillon Tower Advisers Inc. grew its holdings in CymaBay Therapeutics by 42.5% during the 3rd quarter. Carillon Tower Advisers Inc. now owns 2,061,772 shares of the biopharmaceutical company’s stock valued at $22,844,000 after buying an additional 614,502 shares in the last quarter. Redmile Group LLC grew its holdings in CymaBay Therapeutics by 1.2% during the 3rd quarter. Redmile Group LLC now owns 2,993,565 shares of the biopharmaceutical company’s stock valued at $33,169,000 after buying an additional 35,800 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in CymaBay Therapeutics during the 3rd quarter valued at approximately $693,000. 97.97% of the stock is owned by institutional investors and hedge funds.

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Read More: Options Trading – Understanding Strike Price

Receive News & Ratings for CymaBay Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.